SCHEMBL5135367

SCHEMBL5135367

CCCCn1c(CN(Cc2ccc(OC)c(CO)c2)CC2CCCCC2)cnc1-c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
LTC4S Q16873 2/20 0.34
DRD1 P21728 4/20 0.34
DRD4 P21917 4/20 0.34
HTR2C P28335 4/20 0.34
DRD3 P35462 4/20 0.34
DRD5 P21918 2/20 0.34
DRD2 P14416 2/20 0.34
CXCR3 P49682 4/20 0.33
BCHE P06276 2/20 0.32
TSHR P16473 1/20 0.32
OXTR P30559 1/20 0.32
AVPR1A P37288 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5153260 0.88 MEN1 (0.38) C5AR1MEN1KMT2ALMNAPOLB
SCHEMBL5134721 0.87 SMN1; SMN2 (0.39) MEN1KMT2ALMNAPOLBTDP1
SCHEMBL5134947 0.87 TSHR (0.37) C5AR1BCHETSHR
SCHEMBL5072244 0.84 CXCR3 (0.40) CXCR3
SCHEMBL5072388 0.83 TSHR (0.41) C5AR1KMT2ATSHR
SCHEMBL5135146 0.83 C5AR1 (0.53) C5AR1LMNATDP1TSHR
SCHEMBL5136016 0.83 C5AR1 (0.53) C5AR1LMNATDP1TSHR
SCHEMBL5212722 0.82 AGTR1 (0.43) MEN1KMT2ALMNA
SCHEMBL5212718 0.82 AGTR1 (0.38) C5AR1TSHROXTRAVPR1A
SCHEMBL5137569 0.82 AGTR1 (0.35) C5AR1MEN1KMT2ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed